For Investors
Identify technology, regulatory, and team risks with our physician and biomedical engineer-led framework. Quick Score from $2,500 (24h). Investor Score $15,000 (48h with MD debrief).
Batch Pipeline Screening
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Why Vantage
Get institutional-grade risk assessment without institution-grade timelines or costs
What We Find
Startups fail post-funding
Value loss rate (unvalidated tech)
Outcomes in validation dataset
Risk concordance accuracy
Engineering gaps and design flaws typically invisible to external investors. We validate scalability assumptions.
Study design flaws, endpoint selection bias, and generalizability limits that regulators will challenge.
Predicate strategies and pathway assumptions. Timeline delays average 12-18 months with $1-3M cost impact.
Patent scope, freedom-to-operate risks, and competitive landscape. Defensive patent strategies matter early.
Cross-functional execution risk assessment. Technical gaps in regulatory, clinical, and manufacturing leadership.
Reimbursement pathways, payer concentration risk, and pricing sustainability validated through federal data.
Pricing
From deal screening through final diligence on your top prospects
Volume programs available for portfolio screening and annual deal flow support. Contact us →
Investments without clinical-technical due diligence face 3.2x higher loss rates.
Investment Timeline
Risk intelligence from pipeline screening through portfolio monitoring
Portfolio screening to identify high-risk categories early
Quick Score on top 10 for rapid triage
Investor Score with MD debrief on finalists
Risk-stratified report and recommendations
Milestone tracking and portfolio risk management
Methodology in public
Before you trust an investor-grade read, see the framework run on companies whose outcomes are now public. No private claims, no unnamed founders, no rewrites.
Polyethylene packaging defect, 200K+ implants, $1.5B liability, Chapter 11 in 2024. We walk the technology and supply-chain signals that were public years earlier.
Read the retrospective →First FDA-cleared prescription digital therapeutic, $1.6B SPAC valuation, bankruptcy two years later. The coverage and prescribing-economics gaps were knowable pre-deal.
Read the retrospective →FDA warning letter forced a category change from wellness to medical device, halting US sales for 18 months. We trace the regulatory trigger from public filings predating the IPO.
Read the retrospective →We don't publish unnamed-client testimonials. When a sponsor allows it, we'll cite them by name. Until then, our work is judged on retrospective accuracy and methodology you can read end to end.
Start with Quick Score to screen your pipeline. Engage for Investor Score on your top prospects.
20 clinical, regulatory, and technical questions every investor should ask — curated by Dr. Arvind Ravinutala (MD) and Aswini Ravinutala (BME).
Download the ChecklistNo email required. No paywall.